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PCLINICAL RESEARCH Clinical Trials
A Randomized Comparison of Paclitaxel-Eluting
Stents Versus Bare-Metal Stents for Treatment
of Unprotected Left Main Coronary Artery Stenosis
Andrejs Erglis, MD, PHD, FESC, FACC,* Inga Narbute, MD,* Indulis Kumsars, MD,*
Sanda Jegere, MD,* Iveta Mintale, MD,* Ilja Zakke, MD, FESC,* Uldis Strazdins, MD,*
Andris Saltups, MD, FACC, FRACP, MRACP†
Riga, Latvia; and Melbourne, Australia
Objectives To optimize percutaneous coronary intervention (PCI) strategy for unprotected left main (LM) disease, we per-
formed a randomized study: intravascular ultrasound (IVUS)-guided bare-metal stent (BMS) or paclitaxel-eluting
stent (PES) implantation after lesion pre-treatment with cutting balloon (CB) for unprotected LM lesions.
Background Recent studies have shown promising results in terms of safety and feasibility for patients with LM disease who
underwent PCI with stent implantation. However, comparison of BMS and PES for LM lesions has not yet been
evaluated.
Methods One hundred three patients were randomly assigned to receive BMS (n  50) or PES (n  53) implantation. All
interventions were IVUS guided, and CB pre-treatment before stenting was performed in all patients. All patients
were scheduled for 6-month follow-up.
Results Baseline clinical characteristics were comparable in both cohorts. Stent implantation was successful in all le-
sions. Follow-up analysis showed binary restenosis in 11 (22%) BMS and in 3 (6%) PES patients (p  0.021). By
IVUS, percentage of neointimal volume obstruction at 6 months was reduced from 25.20  22.02% with BMS to
16.60  17.25% with PES (p  0.02). At 6 months, the major adverse cardiac event-free survival rate was 70%
in BMS and 87% in PES patients (p  0.036).
Conclusions This study demonstrates that PCI of LM with IVUS guidance and CB pre-treatment is safe and effective. No seri-
ous procedure-related complications were observed, and clinical outcomes appeared to be good. Finally, the
findings demonstrate that implantation of PES may be superior to BMS in the large-diameter LM vessel at 6
months, warranting the performance of a large-scale randomized trial. (J Am Coll Cardiol 2007;50:491–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.055t
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meft main (LM) coronary artery disease is associated with a
oor prognosis when treated medically, and its presence is
n indication for coronary artery bypass surgery (CABG) in
any centers (1–3). Several registries and studies show promis-
ng results in terms of safety and feasibility for patients with
M disease who underwent percutaneous coronary inter-
ention (PCI) with stent implantation. However, common
reatment trends and PCI strategy for these challenging and
omplicated lesions are not yet developed (4–7).
Intravascular ultrasound (IVUS) is a useful tool for
reatment guidance in LM atherosclerotic lesions, owing
rom the *Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital,
iga, Latvia; and the †Cabrini Medical Centre and Monash Medical Centre,
elbourne, Australia. Supported by Innovative Medical Foundation.t
Manuscript received September 6, 2006; revised manuscript received March 5,
007, accepted March 6, 2007.o its accuracy in determining vessel dimensions and
rterial wall structure (4,8,9). Additionally, various
laque modification and debulking techniques before
tent implantation have shown improved luminal gain
ith a corresponding reduction in restenosis rates and
arget vessel revascularization compared with plain bal-
oon angioplasty (10 –12).
See page 498
However, prospective studies have not yet been carried
ut to evaluate the use of cutting balloon (CB) in conjunc-
ion with stent deployment as a means to further optimize
oth short- and long-term outcomes for unprotected left
ain disease. There is also no clear answer as to which stentype (i.e., bare-metal or drug-eluting) should be used if
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Paclitaxel Stent for Left Main Stenting August 7, 2007:491–7adequate luminal dimensions can
be achieved after IVUS-guided
lesion pre-treatment.
To optimize PCI strategy for
unprotected LM disease, we
evaluated IVUS-guided bare-
metal stent (BMS) or paclitaxel-
eluting stent (PES) implantation
after lesion pre-treatment with
CB for unprotected LM lesions.
This technique was devised
based on our own previous stud-
ies as well as experiences at other
centers. Our study objectives
were 2-fold: 1) to evaluate in-
hospital and midterm clinical,
angiographic, and IVUS results
in patients who underwent LM
PCI with CB pre-treatment and
IVUS guidance; and 2) to deter-
mine whether BMS or drug-
eluting stents (DES) are more
appropriate for LM stenting in
terms of thrombosis risk, reste-
nosis, and clinical adverse events.
ethods
etween January 2002 and January 2006, we enrolled 203
onsecutive patients with unprotected LM disease under-
oing PCI in our center into the LM PCI registry.
In February 2004, after preliminary successful LM inter-
entions with BMS, we started randomization between
MS and PES. One hundred three (n 103) patients were
andomly assigned to receive Express or Liberte BMS
n  50) or Taxus Express PES (n  53) implantation
all stents manufactured by Boston Scientific Corp., Natick,
assachusetts).
In this randomized cohort (n  103), all interventions
ere performed using IVUS guidance and CB pre-
reatment for atherosclerotic plaque modification before
tenting.
atient population. Eligible patients were those with clin-
cally symptomatic LM disease with angiographic evidence
f50% diameter stenosis of LM suitable for stent implan-
ation. The LM coronary artery was considered unprotected
f there was no CABG to left anterior descending (LAD)
rtery branches or left circumflex (LCX) branches. All
atients were good candidates for CABG. Informed written
onsents were obtained for all patients.
CI procedure. MEDICAL PROTOCOL. A maximum of 24
ours before the PCI procedure, all patients received 100
g aspirin and a loading dose (300 mg) of clopidogrel.
atients were required to take clopidogrel 75 mg daily for at
east 6 months after the PCI procedure. During the proce-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CB  cutting balloon
IVUS  intravascular
ultrasound
LAD  left anterior
descending
LCX  left circumflex
LM  left main
MLA  minimum lumen
area
MLD  minimal lumen
diameter
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
coronary analysis
TLR  target lesion
revascularizationure, all patients were administered 10,000 IU of heparin or wow-molecular-weight heparin depending on the patient’s
eight. Glycoprotein IIb/IIIa receptor inhibitors were given
t the operator’s discretion.
NGIOGRAPHY. Coronary angiography was performed after
ntracoronary administration of nitroglycerine (0.2 mg).
uantitative coronary angiography (QCA) was performed
ff line, using a computer-based QCA-CMS system, ver-
ion 4.0 (Medis Medical Imaging Systems, Leiden, the
etherlands), by the Riga core lab. The percentage diameter
tenosis and minimal lumen diameter (MLD) were mea-
ured from diastolic frames before and after the PCI
rocedure and at 6-month follow-up. Angiographic reste-
osis was defined as 50% diameter stenosis at follow-up.
VUS PROTOCOL. The IVUS images were obtained using the
ommercial IVUS system Galaxy II (Boston Scientific Corpo-
ation) and motorized pull-back at 0.5 mm/s. Pre- and
ost-procedure IVUS images were obtained for all patients,
nd follow-up IVUS images were obtained for 46 patients in
he BMS group and 44 patients in the PES group. Analyses
ere performed by the Riga core lab. Longitudinal reconstruc-
ion of IVUS images was performed using a computer-based
uantitative analysis system (QCU-CMS version 4.14, Medis
edical Imaging Systems). After digitalization of IVUS re-
ordings at a frame rate of 30 images/s, longitudinal views of
he studied segments were automatically processed. Using
easurements from pre-interventional images, the lesion seg-
ent was classified as a culprit lesion with 5 mm of proximal
nd distal reference (most normal-appearing) segments. The
orresponding frames at intervention stages, post-intervention,
nd follow-up were determined using peri- and intravascular
andmarks (side branches, calcium, perivascular structures)
rom longitudinally reconstructed images. Vessel, stent, and
umen contours were automatically detected and manually
orrected at 6-frame intervals; interpolated measurements of
he remaining frames were automatically generated. In-stent
ate loss in lumen diameter (or lumen area) was calculated as
ost-procedural MLD (or minimum lumen area [MLA])
inus follow-up MLD (or MLA). In addition to standard
VUS measurements (MLD, MLA, and late loss), neointimal,
umen, stent, vessel, and plaque volumes were calculated at the
esion site. Neointimal volume index was calculated as neoin-
imal volume divided by segment length. Percentage neointi-
al volume obstruction was defined as the ratio of the volume
f neointimal hyperplasia to the volume of the stent multiplied
y 100.
The IVUS and QCA measurements were performed by
ndependent observers blinded to the treatment arm.
UTTING BALLOON INTERVENTION. The CB intervention
as performed with a balloon-to-vessel ratio of 1:1, according
o the IVUS media-to-media to the vessel at the lesion site, to
chieve pre-specified IVUS criteria of MLA 9.0 mm2 after
tenting. The CB intervention was performed to cover the
ntire lesion length. Balloon inflations were performed 3 times
ith increasing pressure throughout the lesion.
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August 7, 2007:491–7 Paclitaxel Stent for Left Main StentingTENT IMPLANTATION. After CB intervention, IVUS was
erformed to evaluate stent length and diameter.
All lesions at the ostium and body were treated with a
ingle stent implantation. If the distal portion of the LM or
bifurcation was involved, the following stenting strategies
ere used. For most cases, stenting across the LCX ostium
r provisional T stenting (if LCX ostium and/or proximal
art was severely diseased) was performed. Final kissing
alloon dilation was performed only in cases with subopti-
al result at the LCX ostium. In other cases, a good result
as achieved by opening the stent strut to the LCX with a
mall-diameter balloon or just after stent implantation.
After stent implantation, subsequent IVUS was per-
ormed to evaluate stent apposition and residual stenosis. If
ny segment on the treated vessel did not meet success
riteria, additional balloon dilations with the noncompliant
alloon were performed.
ollow-up. All patients were scheduled for clinical, angio-
raphic, and IVUS follow-up at 6 months. All patients were
lso evaluated clinically during an office visit or by phone at
month. Repeat coronary angiography and IVUS evalua-
ion was performed routinely at 6 months, or earlier if
linically indicated. The IVUS was performed to evaluate
eointimal growth (volume, square, luminal diameter, and
ate lumen loss).
efinitions. Major adverse cardiac events (MACE) were
efined as death, myocardial infarction (MI), and target
esion revascularization (TLR). Patients with more than 1
vent were assigned the highest rank event. All deaths were
onsidered to be of cardiac origin unless a noncardiac origin
as diagnosed. Myocardial infarction (MI) was diagnosed
y elevation of myocardial damage biomarkers: 3-fold in
roponin I and 5-fold in MB fraction of creatine kinase.
arget lesion revascularization was defined as a repeat
ntervention (surgical or percutaneous) to treat a luminal
tenosis in the stent or within the 5-mm segments adjacent
o the stent, including the ostium of the LAD artery and/or
CX artery.
The PCI procedure was considered to be successful
procedure success) if the treated segment satisfied either
f the following 2 success criteria: MLA 9.0 mm2 by
VUS or residual angiographic stenosis 10% (if the
inimal luminal reference vessel size by IVUS was
maller than 9.0 mm2).
tatistics. Data were analyzed using SPSS (Statistical
ackage for the Social Sciences) software. Continuous
ariables are expressed as mean  SD. Categoric variables
ere tested using contingency tables analyses (exact or
hi-square approximations), and continuous variables were
ested using unpaired Student t test or Wilcoxon rank-sum
est, depending on variable distribution. All statistical tests
ere 2-sided, and a p value of 0.05 was considered to be
tatistically significant. Survival curves were generated with
he Kaplan-Meier method and were compared by use of the
og rank test. All data for QCA and IVUS refer to the
ff-line analysis.
f
tesults
atient characteristics. From February 2004 to November
005, a total 103 randomized patients with unprotected LM
tenosis underwent stent implantation with either BMS
n  50) or PES (n  53). Baseline clinical characteristics
re presented in Table 1. Overall, there were no significant
ifferences in baseline characteristics. The mean age of
atients was 61.80  10.84 years, the majority of patients
ere male (83%,) and the rate of hyperlipidemia was very
igh in both groups (BMS 68%, PES 81%; p  0.173).
aseline lesion and procedural characteristics. The base-
ine angiographic characteristics are summarized in Table 2.
rocedural success was achieved in 100% of patients in both
roups; however, there was 1 intraprocedural complication:
erforation after CB intervention (successfully resolved with
MS stent implantation). Fifty patients (49%) underwent a
ercutaneous intervention in another major coronary seg-
ent as well.
There was a trend toward higher mean pre-procedural
essel diameter in the PES group compared with the
MS group (3.13  0.74 mm vs. 3.38  0.63 mm; p 
.070). Mean treated segment length was comparable
etween the 2 treatment groups (11.49  4.07 mm in
ES vs. 11.64  4.10 mm in BMS; p  0.960).
To cross the lesion with the IVUS catheter, pre-dilation
ith a small balloon was used in 13 cases (26%) in the BMS
roup (diameter 2.50 0.46 mm, length 21.23 4.04 mm,
ean pressure 11.69  3.99 atm) and 6 (11%) in the PES
roup (diameter 2.33 0.41 mm, length 21.33 9.69 mm,
ean pressure 12.83  4.12 atm), although these differ-
nces did not reach statistical significance. Two-stent strat-
gy (T stent method) was used in 1 case (2%) in the BMS
roup and 1 (2%) in the PES group (p  0.99).
aseline Characteristics
Table 1 Baseline Characteristics
BMS (n  50) PES (n  53) p Value
Mean age, mean  SD (yrs) 62.56 11.45 61.08 10.28 0.490
Male gender, n (%) 41 (82) 45 (85) 0.793
Smoking status, n (%)
Current smoker 11 (22) 14 (26) 0.651
Past smoker 12 (24) 15 (28) 0.660
Medical history, n (%)
Diabetes mellitus 6 (12) 6 (11) 0.99
Hypertension 25 (50) 31 (59) 0.432
Hyperlipidemia 34 (68) 43 (81) 0.173
Previous MI 20 (40) 30 (57) 0.116
Indication for PCI, n (%)
Stable angina 41 (82) 43 (81) 0.99
Acute coronary syndrome 8 (16) 10 (19) 0.798
Silent ischemia 1 (2) 0 (0) 0.485
Prior PCI, n (%) 21 (42) 19 (36) 0.550
Prior CABG, n (%) 4 (8) 2 (4) 0.428
LVEF, mean  SD (%) 53.55 10.64 56.33 11.23 0.377
MS  bare-metal stent; CABG  coronary artery bypass grafting; LVEF  left ventricular ejection
raction by echocardiography; MI  myocardial infarction; PCI  percutaneous coronary interven-
ion; PES  paclitaxel-eluting stent.
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Paclitaxel Stent for Left Main Stenting August 7, 2007:491–7To optimize stent apposition, post-dilation with a larger
alloon or noncompliant balloon was needed in 26 cases (52%)
n the BMS group and 36 (68%) in the PES group (p 0.111).
There were no significant differences observed in terms of
linical or IVUS results for “kissing post-dilation” compared
ith stent struts opened by small balloon. There were no
ncidents of death, stent thrombosis, Q-wave MI, or emer-
ent bypass surgery during hospitalization in either group.
ngiographic results. Angiographic results are presented
n Table 3. Six-month angiographic follow-up and QCA
nalysis were performed for all 103 patients (100%).
ollow-up analysis showed binary restenosis (50% diam-
ter stenosis by QCA) in 11 (22%) in BMS and in 3 (6%)
n PES patients (p  0.021). There were no differences
Angiographic Characteristics
Table 2 Angiographic Characteristics
BM
LM lesion location, n (%)
Ostium
Body
Distal (bifurcation)
Mean CB diameter, mm 3
CB maximal inflation pressure, atm 10
Number of stents, n 1
Patients with 1 stent implanted, n (%)
T stent method, n (%)
Mean stent length, mm 14
Mean stent diameter, mm 3
Maximal stent implantation pressure, atm 11
Post-dilation, n (%)
Maximal post-dilation pressure, atm 13
Kissing balloon, n (%)
Opened strut to LCX, n (%)
Glycoprotein IIb/IIIa inhibitors, n (%)
IABP use, n (%)
Values are n (%) or mean SD.
IABP  intra-aortic balloon pump; LCX  left circumflex; LM  left
Angiographic Characteristics at the Procedure a
Table 3 Angiographic Characteristics at the
Lesion length
Pre-intervention
MLD, mm
Reference diameter, mm
Diameter stenosis, %
Post-intervention
MLD, mm
Reference diameter, mm
Diameter stenosis, %
6-month follow-up
MLD, mm
Reference diameter, mm
Diameter stenosis, %
Angiographic restenosis rate (binary), n (%)Values are mean SD. Quantitative coronary analysis was used for in-stent m
MLD  minimal lumen diameter; other abbreviations as in Table 1.ound regarding if lesion were located in ostium, body, or
istal bifurcation.
VUS results. The IVUS images were analyzable for 90
atients (87%; BMS n  46 [92%]; PES n  44 [83%]). In
he PES group, statistically significant differences were
bserved in MLD late loss as well as in MLA late loss and
eointimal volume compared with BMS. The MLD late
oss in the DES group was 0.22  0.22 versus 0.60  0.33
n the BMS group (p  0.001), and MLA late loss in the
ES group was 1.07 0.85 versus 2.70 1.54 in the BMS
roup (p 0.001). Also neointimal volume at 6 months was
ignificantly reduced in the DES group 17.22  17.10
ersus 25.98  21.84 in the BMS group (p  0.014). Main
rocedural and 6-month follow-up IVUS measurements are
 50) PES (n  53) p Value
4) 2 (4) 0.087
8) 8 (15) 0.793
8) 43 (81) 0.173
0.23 3.78 0.57 0.313
2.39 9.69 2.52 0.453
0.14 1.02 0.14 0.967
) 1 (2) 0.99
) 1 (2) 0.99
6.24 20.98 7.73 0.001
0.14 3.49 0.25 0.001
2.50 13.23 3.23 0.016
2) 36 (68) 0.111
2.53 14.83 2.54 0.038
) 10 (19) 0.074
) 13 (25) 0.033
2) 43 (81) 0.352
) 0 (0) —
ther abbreviations as in Table 1.
t 6 Months After Implantation
edure and at 6 Months After Implantation
n  50) PES (n  53) p Value
 4.07 11.64 4.10 0.960
 0.51 1.23 0.56 0.737
 0.74 3.38 0.63 0.070
 15.63 62.75 17.97 0.762
 0.45 3.05 0.40 0.639
 0.53 3.56 0.42 0.963
 10.44 13.82 8.36 0.731
 0.67 2.74 0.45 0.086
 0.54 3.23 0.46 0.804
 15.52 15.80 9.43 0.037
(22) 3 (6) 0.021S (n
7 (1
9 (1
34 (6
.87
.06
.02
1 (2
1 (2
.02
.96
.82
26 (5
.50
3 (6
4 (8
36 (7
0 (0nd a
Proc
BMS (
11.49
1.14
3.13
63.80
3.01
3.56
14.00
2.52
3.20
21.81
11easurements.
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August 7, 2007:491–7 Paclitaxel Stent for Left Main Stentingummarized in Table 4. There were no differences found
egarding lesion localization in the main stem.
linical outcomes. In-hospital non–Q-wave MI was de-
ected in 6 BMS patients (12%) and 4 DES patients (8%;
 0.518).
Clinical follow-up data were available for all patients in
oth treatment groups. At 6 months there was 1 (2%)
oncardiac death in the BMS group and 1 (2%) cardiac
eath in the PES group (p  0.99). The incidence of
-wave MI at 6 months was equal in both groups: 1 (2%)
n the BMS group and 1 (2%) in the DES group (p 0.99).
o late stent thromboses were detected. Target lesion
evascularization was performed in 8 BMS patients (16%)
nd 1 PES patient (2%; p  0.014). All TLRs were
linically indicated, based on recurrent angina or positive
tress test.
See Table 5 for detailed clinical outcomes.
At 6 months, the major adverse cardiac event-free sur-
ival rate was 70% in the BMS group and 87% in the PES
roup (p  0.036) (Fig. 1).
iscussion
ince the first reports of percutaneous treatment of LM
oronary artery stenosis, there has been debate over whether
o treat these challenging lesions with surgery or percuta-
eous revascularization. Coronary artery bypass graft sur-
ery has been demonstrated to prolong survival in patients
ith significant LM stenosis compared with medically
reated patients (3).
Several studies and registries on percutaneous revascular-
zation of LM stenosis have been conducted; however, many
ave included only small patient numbers in nonrandom-
IVUS Characteristics at the Procedure and at 6
Table 4 IVUS Characteristics at the Proced
In-Stent Analysis BMS
Post-intervention
MVD, mm 4.5
EEM area, mm2 18.1
MLD, mm 3.3
MLA, mm2 9.2
Malapposition, n (%)
6-month follow-up
MVD, mm 4.8
EEM area, mm2 20.2
MLD, mm 2.9
MLA, mm2 7.3
Late loss in lumen diameter, mm 0.6
Late loss in lumen area, mm2 2.7
Neointimal volume, mm3 25.9
Neointimal volume index, mm3/mm 1.8
% neointimal volume obstruction, % 25.2
Malapposition, n (%)
Values are mean  SD.
EEM  external elastic membrane; IVUS  intravascular ultrasoun
abbreviations as in Table 3.zed cohorts. The ULTIMA (Unprotected Left Main
M
arunk Intervention Multicenter Assessment) registry dem-
nstrated high subacute cardiac mortality between high-risk
atients and those with a low left ventricular ejection
raction (13,14). Therefore, the present study included only
atients with well preserved left ventricular function in
hom a good long-term prognosis could be expected if stent
lacement was successful.
ths After Implantation
nd at 6 Months After Implantation
46) PES (n  44) p Value
51 4.47 0.53 0.528
72 16.66 3.37 0.535
36 3.26 0.31 0.414
56 8.68 1.59 0.100
0 (0) —
50 4.68 0.50 0.149
91 17.71 3.10 0.001
54 3.04 0.40 0.164
55 7.57 1.91 0.665
33 0.22 0.22 0.001
54 1.07 0.85 0.001
.84 17.22 17.10 0.014
20 0.86 0.62 0.001
.02 16.60 17.25 0.023
0 (0) —
 minimum lumen area; MVD  minimum vessel diameter; other
linical Outcomes
Table 5 Clinical Outcomes
BMS (n  50) PES (n  53) p Value
In-hospital outcomes
Death, n (%) 0 (0) 0 (0) —
Cardiac death, n (%) 0 (0) 0 (0) —
MI (total), n (%) 6 (12) 4 (8) 0.518
Q-wave MI, n (%) 0 (0) 0 (0) —
Non–Q-wave MI, n (%) 6 (12) 4 (8) 0.518
Stent thrombosis 0 (0) 0 (0) —
TLR, n (%) 0 (0) 0 (0) —
TLR-PCI, n (%) 0 (0) 0 (0) —
TLR-CABG, n (%) 0 (0) 0 (0) —
MACE, n (%) 6 (12) 4 (8) 0.518
6-month cumulative outcomes
Total death, n (%) 1 (2) 1 (2) 0.99
Cardiac death, n (%) 0 (0) 1 (2) 0.99
MI (total), n (%) 7 (14) 5 (9) 0.548
Q-wave MI, n (%) 1 (2) 1 (2) 0.99
Non–Q-wave MI, n (%) 6 (12) 4 (8) 0.518
TLR, n (%) 8 (16) 1 (2) 0.014
TLR-PCI, n (%) 8 (16) 1 (2) 0.014
TLR-CABG, n (%) 0 (0) 0 (0) —
MACE, n (%) 15 (30) 7 (13) 0.054Mon
ure a
(n 
5 0.
0 3.
3 0.
8 1.
0 (0)
3 0.
0 3.
0 0.
6 2.
0 0.
0 1.
8 21
3 1.
0 22
0 (0)ACE major adverse coronary event; TLR  target lesion revascularization; other abbreviations
s in Table 1.
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Paclitaxel Stent for Left Main Stenting August 7, 2007:491–7Anatomically, left main distal lesions are bifurcation
esions. We support the use of 1 stent in bifurcation lesions
o reduce acute complications (stent thrombosis, significant
levations of myocardial biomarkers) as well as the resteno-
is rate and need for repeat revascularization at the target
egment (15,16). Performing main branch stenting, in LM
ases means stenting across the ostium of the LCX artery,
hich presents the problem of plaque shifting to the LCX
stium. This may be avoided by pre-treating the lesion bed
n the LAD artery as well as the LCX ostium with CB
efore stent deployment in the LM and deploying an
dditional stent in the LCX only in cases of severe disease in
he LCX ostium and/or proximal portion. Good stent
pposition may be achieved with lesion pre-treatment even
ithout final kissing, which can be an additional unwanted
actor for ischemia.
ole of IVUS guidance. There is no doubt that IVUS
llows much more accurate assessment of lumen size, plaque
rea, and intimal composition compared with coronary
ngiography and QCA analysis (4,9). In the present study
e used an IVUS-guided strategy for all LM percutaneous
nterventions. Some studies have demonstrated no differ-
nce in terms of restenosis rate between IVUS-guided and
ngiography-guided LM PCI procedures (4). This may be
xplained by the large reference vessel diameter; and, as we
now from previous studies (MUSIC [Multicenter Ultra-
ound Guided Stent Implantation in the Coronaries]),
ost-interventional MLD and MLA are the most impor-
Figure 1 Kaplan-Meier Curves: Freedom
From Major Adverse Coronary Events
At 6 months, the death, myocardial infarction, and target lesion revasculariza-
tion (major adverse coronary events)-free survival rate was 70.0% in the bare-
metal stent (BMS) group and 86.8% in the paclitaxel-eluting stent (PES) group
(p  0.036). PCI  percutaneous coronary intervention.ant predictors of restenosis (17). wDespite this evidence, IVUS guidance may be necessary
n such a delicate and high-risk lesion cohort as LM
tenoses for detection of exact plaque borders, verification of
tent apposition, and geometry. However, an appropriately
owered randomized trial of LM stenting with versus
ithout IVUS is required before IVUS use can be consid-
red mandatory in this lesion subset.
ole of CB pre-treatment. In large vessels, large MLD
an be achieved after stent deployment by using only
igh-pressure balloon dilation. If necessary, atherosclerotic
laque modification will allow further stent expansion,
lthough whether this improves the long-term outcomes of
tent implantation is unknown.
Several debulking devices exist for reducing atheroscle-
otic plaque burden before stenting and for reducing subse-
uent restenosis as well (18,19). We found CB to be a
easonable tool for pre-treatment of atherosclerotic plaque
efore stent deployment. However, a randomized trial of
eft main stenting with versus without CB plaque modifi-
ation is required to establish the safety of benefits of this
echnique. Moreover, whether CB sizing is best determined
y IVUS guidance has not been established, but it seems a
ore reasonable tool for precise vessel dimension assessment.
ole of DES versus BMS. Starting with the RAVEL
Randomized Comparison of a Sirolimus-Eluting Stent
ith a Standard Stent for Coronary Revascularization) trial,
umerous studies have demonstrated the benefits of DES
ver BMS in different lesion cohorts. Even in patients with
ultivessel disease in the ARTS II (Arterial Revasculariza-
ion Therapies Study II) (20), DES was not associated with
n increased need for repeat revascularization compared
ith CABG. Those excellent results allowed the extension
f DES implantation to unprotected LM disease (21–23).
Our unprotected LM PCI registry was initiated long
efore the first DES became available in our institution. In
ddition, our strategy of IVUS-guided plaque pre-treatment
ith CB before stent deployment produced excellent results
ith BMS. Using DES, we are encouraged to treat longer
egments to cover LM and proximal LAD. Thus, the stent
ize was matched to the LAD reference vessel diameter, and
hen the LM segment of the stent was further expanded
ith a larger-size noncompliant balloon if necessary. An-
iographic appearance of the lesions often differs from
VUS data. Thus, there were discrepancies between lesion
nd deployed stent lengths.
The availability of DES has prompted the question:
hould we use DES in all LM cases? Does DES provide
enefit in such large-diameter vessels as LM? The present
mall prospective randomized study suggests that PES may
e superior to BMS in unprotected LM stenoses.
The ongoing prospective multicenter randomized
YNTAX (Synergy Between PCI and Taxus and Cardiac
urgery) study promises to answer many more critical
uestions regarding the relative efficacy of DES compared
ith CABG.
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August 7, 2007:491–7 Paclitaxel Stent for Left Main Stentingtudy limitations. The present study was carried out in a
ingle center and had an open-label design. The study was
nderpowered by the small sample size. Furthermore, only
ntermediate-term (6 months) results were available.
onger-term follow-up in larger numbers of patients is
equired to establish the risk of early and stent thrombosis
fter thienopyridine discontinuation and to explore the
ptimal duration of dual antiplatelet therapy. Moreover, the
odest sample size and open-label nature of the present
rial led to differences between the 2 arms in vessel size,
tent length and diameter, and inflation pressure. The
xtent to which these differences contributed to the ob-
erved results is unknown. Finally, larger registries and
andomized trials are required to explore the optimal tech-
ique of LM stenting, especially when the distal bifurcation
s involved, including 1- versus 2-stent technique, and the
tility of IVUS guidance and plaque medication.
onclusions
he present study suggests that percutaneous revasculariza-
ion of LM with IVUS guidance and CB pre-treatment may
e safe and effective. No serious procedure-related compli-
ations were observed, and intermediate-term outcomes
ere favorable. Finally, the findings of this study suggest
hat PES are superior to BMS in the large-diameter LM
essel at 6 months.
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